natgillin/translations-raw huggingface dataset:
The company that markets Leflunomide Zentiva will ensure that doctors who are expected to prescribe the medicine receive an information pack containing important information on the risks with Leflunomide Zentiva and the monitoring that should be carried out in patients. 
Podjetje, ki trži zdravilo Leflunomid Zentiva, bo zagotovilo, da bodo zdravniki, ki naj bi predpisovali zdravilo, prejeli informativno gradivo s pomembnimi informacijami o tveganjih, povezanih z zdravilom Leflunomid Zentiva, in o spremljanju, ki ga je treba izvajati pri bolnikih.
What benefits of Leflunomide Zentiva have been shown in the studies? 
Kakšne koristi zdravila Leflunomid Zentiva so se pokazale v študijah?
In psoriatic arthritis, a study in 186 patients showed that Leflunomide Zentiva was more effective than placebo over 6 months: 59% of the patients taking Leflunomide Zentiva responded to treatment, compared with 30% of those taking placebo. 
Študija psoriatičnega artritisa, v kateri je sodelovalo 186 bolnikov, je pokazala, da je bilo zdravilo Leflunomid Zentiva v šestih mesecih učinkovitejše od placeba: na zdravljenje se je odzvalo 59 % bolnikov, ki so jemali zdravilo Leflunomid Zentiva, v primerjavi s 30 % bolnikov, ki so jemali placebo.
The active substance in Leflunomide Zentiva, leflunomide, is an immunosuppressant. 
Učinkovina v zdravilu Leflunomid Zentiva, leflunomid, je imunosupresiv.
Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Leflunomide Zentiva have been included in the summary of product characteristics and the package leaflet. 
Priporočila in varnostni ukrepi, ki jih morajo za varno in učinkovito uporabo zdravila Leflunomid Zentiva upoštevati zdravstveni delavci in bolniki, so vključeni v povzetek glavnih značilnosti zdravila in navodilo za uporabo.
Leflunomide Zentiva is a medicine used to treat adults with active rheumatoid arthritis (an immune system disease causing inflammation of the joints) or active psoriatic arthritis (a disease causing red, scaly patches on the skin and inflammation of the joints). 
Leflunomid Zentiva je zdravilo, ki se uporablja za zdravljenje odraslih z aktivnim revmatoidnim artritisom (boleznijo imunskega sistema, ki povzroča vnetje sklepov) ali aktivnim psoriatičnim artritisom (boleznijo, ki povzroča rdeče, luskaste zaplate na koži in vnetje sklepov).
Side effects reported with Leflunomide Zentiva are carefully evaluated and any necessary action taken to protect patients. 
Neželeni učinki, o katerih so poročali pri zdravilu Leflunomid Zentiva, se skrbno ovrednotijo in po potrebi se sprejmejo ukrepi za zaščito bolnikov.
Why is Leflunomide Zentiva authorised in the EU? 
Zakaj je zdravilo Leflunomid Zentiva odobreno v EU?
It can only be obtained with a prescription and treatment should be started and supervised by a specialist who has experience in the treatment of rheumatoid arthritis and psoriatic arthritis. 
Predpisovanje in izdaja zdravila je le na recept, zdravljenje z njim pa mora uvesti in nadzorovati zdravnik specialist, ki ima izkušnje z zdravljenjem revmatoidnega in psoriatičnega artritisa.
An overview of Leflunomide Zentiva and why it is authorised in the EU 
Pregled zdravila Leflunomid Zentiva in zakaj je odobreno v EU
For more information about using Leflunomide Zentiva, see the package leaflet or contact your doctor or pharmacist. 
Za več informacij o uporabi zdravila Leflunomid Zentiva glejte navodilo za uporabo ali se posvetujte z zdravnikom ali farmacevtom.
With fewer lymphocytes, there is less inflammation, helping to control the symptoms of arthritis. 
Z zmanjšanjem števila limfocitov se zmanjša tudi vnetje, kar pripomore k obvladovanju simptomov artritisa.
What is Leflunomide Zentiva and what is it used for? 
Kaj je zdravilo Leflunomid Zentiva in za kaj se uporablja?
Other information about Leflunomide Zentiva 
Druge informacije o zdravilu Leflunomid Zentiva
In rheumatoid arthritis, Leflunomide Zentiva has been studied in 4 main studies involving over 2,000 patients, in which it was compared with placebo (a dummy treatment), or with methotrexate or sulphasalazine (other medicines used to treat rheumatoid arthritis). 
Pri revmatoidnem artritisu so zdravilo Leflunomid Zentiva proučevali v štirih glavnih študijah, v katere je bilo vključenih več kot 2 000 bolnikov in v katerih so zdravilo primerjali s placebom (zdravilom brez učinkovine) ali metotreksatom ali sulfasalazinom (drugima zdravilom za zdravljenje revmatoidnega artritisa).
It reduces inflammation by reducing the production of immune cells called ‘lymphocytes', which are responsible for inflammation. 
Ta učinkovina zmanjšuje vnetje z zaviranjem tvorbe imunskih celic, imenovanih „limfociti“, ki so odgovorni za vnetje.
Leflunomide does this by blocking an enzyme called ‘dihydroorotate dehydrogenase', which is necessary for the lymphocytes to multiply. 
Do tega pride z zaviranjem encima, imenovanega „dihidroorotat dehidrogenaza“, ki je potreben za razmnoževanje limfocitov.
What are the risks associated with Leflunomide Zentiva? 
Kakšna tveganja so povezana z zdravilom Leflunomid Zentiva?
Leflunomide Zentiva was not as effective as methotrexate in the extension study. 
Zdravilo Leflunomid Zentiva v podaljšani študiji ni bilo tako učinkovito kot metotreksat.
They also need to take special care when switching a patient to Leflunomide Zentiva, or when switching a patient who is receiving Leflunomide Zentiva to another treatment. 
Prav tako morajo posebno pozornost nameniti prehodu na zdravilo Leflunomid Zentiva oziroma prehodu z zdravila Leflunomid Zentiva na drugo zdravilo.
The doctor should carry out blood tests to check the patient's liver, white blood cell counts and platelet counts before prescribing Leflunomide Zentiva, and regularly during treatment. 
Zdravnik mora pred predpisovanjem zdravila Leflunomid Zentiva in redno med zdravljenjem pri bolniku opraviti krvne preiskave, da preveri delovanje jeter, število belih krvnih celic in trombocitov.
For the full list of side effects with Leflunomide Zentiva, see the package leaflet. 
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Leflunomid Zentiva, glejte navodilo za uporabo.
How is Leflunomide Zentiva used? 
Kako se zdravilo Leflunomid Zentiva uporablja?
The medicine contains the active substance leflunomide. 
Vsebuje učinkovino leflunomid.
How does Leflunomide Zentiva work? 
Kako zdravilo Leflunomid Zentiva deluje?
The tablets are swallowed whole with water. 
Tablete je treba pogoltniti cele z vodo.
It is available as tablets (0.5 and 1 mg). 
Na voljo je v obliki tablet (0,5 mg in 1 mg).
The European Commission granted a marketing authorisation valid throughout the European Union for Champix on 26 September 2006. 
Evropska komisija je dovoljenje za promet z zdravilom Champix, veljavno po vsej Evropski uniji, izdala 26. septembra 2006.
Treatment with Champix lasts for 12 weeks. 
Zdravljenje z zdravilom Champix traja 12 tednov.
The full EPAR for Champix can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Champix je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
This is a summary of the European public assessment report (EPAR) for Champix. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Champix.
Treatment with Champix is more likely to succeed in smokers who are motivated to stop smoking and who are also receiving additional advice and support. 
Uspeh zdravljenja z zdravilom Champix je verjetnejši pri kadilcih, ki so motivirani za opustitev kajenja in so deležni dodatnega svetovanja in podpore.
What measures are being taken to ensure the safe and effective use of Champix? 
Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Champix?
For more information about treatment with Champix, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Champix preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
A risk management plan has been developed to ensure that Champix is used as safely as possible. 
Za zagotovitev čim varnejše uporabe zdravila Champix je bil pripravljen načrt obvladovanja tveganj.
The CHMP concluded that the benefits of Champix outweigh its risks and recommended that it be given marketing authorisation. 
CHMP je zaključil, da so koristi zdravila Champix večje od z njim povezanih tveganj, in priporočil, da se zanj izda dovoljenje za promet.
The main measure of effectiveness was the number of patients who had completely stopped smoking for four weeks (between week 9 and week 12 of the study), confirmed by laboratory testing of the patients' breath for signs of smoking. 
Glavno merilo učinkovitosti je bilo število bolnikov, ki so za štiri tedne (med 9. in 12. tednom študije) popolnoma opustili kajenje, kar so preverjali z laboratorijskimi preiskavami izdihanega zraka bolnikov, v katerem so iskali znake kajenja.
The most common side-effects with Champix (seen in more than 1 patient in 10) are nausea (feeling sick), insomnia (difficulty sleeping), abnormal dreams, headache and nasopharyngitis (inflammation of the nose and throat). 
Najpogostejši neželeni učinki zdravila Champix (opaženi pri več kot 1 bolniku od 10) so slabost, nespečnost, neobičajne sanje, glavobol in nazofaringitis (vnetje nosu in grla).
Other information about Champix 
Druge informacije o zdravilu Champix
In two main studies 2,052 smokers received 12-week treatment with Champix, bupropion (another non-nicotine medicine) or placebo (a dummy treatment). 
V dveh glavnih študijah je sodelovalo 2 052 kadilcev, ki so 12 tednov prejemali zdravilo Champix, bupropion (drugo ne-nikotinsko zdravilo) ali placebo (zdravilo brez zdravilne učinkovine).
In the first week the patient takes one 0.5 mg tablet once a day for three days, followed by one 0.5 mg tablet twice a day for four days. 
V prvem tednu se tri zaporedne dni enkrat na dan vzame 0,5-miligramska tableta, preostale štiri dni pa ena 0,5-miligramska tableta dvakrat na dan.
Champix is a medicine that contains the active substance varenicline. 
Champix je zdravilo, ki vsebuje zdravilno učinkovino vareniklin.
The percentage in the patients who had taken bupropion was 16%. 
Za razliko od tega je bilo v skupini, ki je jemala bupropion, takih oseb 16 %.
What benefit has Champix shown during the studies? 
Kakšne koristi je zdravilo Champix izkazalo med študijami?
For the remaining 11 weeks of treatment, the patient takes one 1 mg tablet twice a day. 
Ostalih 11 tednov se jemlje ena 1-miligramska tableta dvakrat na dan.
The percentage of patients who had not smoked at all during weeks 9-12 was 44% with Champix, 30% with bupropion, and 18% with placebo. 
Odstotek bolnikov, ki so popolnoma prenehali kaditi v obdobju od 9. do 12. tedna, je bil pri zdravilu Champix 44 %, pri bupropionu 30 % in pri placebu 18 %.
The patients' target date for quitting was set at one week after starting treatment and the patients were followed up for a further 40 weeks after their treatment to see if they started smoking again. 
Ciljni datum opustitve kajenja je bil postavljen en teden po začetku zdravljenja, vse preizkušance pa so opazovali še nadaljnjih 40 tednov po koncu zdravljenja, da bi videli, ali so znova začeli kaditi.
Patients who are unwilling or unable to set a target date within one to two weeks could be offered the treatment first and then later choose their target date to fall within five weeks of starting treatment. 
Osebam, ki ne želijo ali ne morejo postaviti datuma v roku enega ali dveh tednov, se najprej ponudi zdravljenje, ciljni datum pa si postavijo kasneje, in sicer v petih tednih od začetka zdravljenja.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Champix, including the appropriate precautions to be followed by healthcare professionals and patients. 
V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Champix in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
Champix is used in adults to help them stop smoking. 
Zdravilo Champix se uporablja pri odraslih kot pomoč pri odvajanju od kajenja.
When binding to these receptors, varenicline acts in two ways: it acts like nicotine (partial agonist) and this helps to relieve craving symptoms, but it also acts against nicotine (antagonist), by taking its place, and this helps to reduce the pleasurable effects of smoking. 
Vareniklin z vezavo na te receptorje deluje na dva načina: deluje kot nikotin (delni agonist) in s tem blaži simptome hlepenja, istočasno pa deluje tudi proti nikotinu (antagonist), saj preprečuje vezavo nikotina in s tem zmanjšuje s kajenjem povezane občutke ugodja.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Champix. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
In both studies, Champix was more effective than bupropion or placebo in helping patients to stop smoking. 
V obeh študijah je zdravilo Champix v primerjavi z bupropionom oziroma placebom učinkoviteje pripomoglo k opustitvi kajenja.
For the full list of all side effects and restrictions with Champix, see the package leaflet. 
Za celoten seznam vseh neželenih učinkov in omejitev pri uporabi zdravila Champix glejte navodilo za uporabo.
People who smoke become addicted to nicotine, a chemical in tobacco. 
Kadilci polagoma postanejo zasvojeni z nikotinom, ki je kemična snov v tobaku.
Reduced doses may be used in patients who do not tolerate the medicine or who have kidney problems. 
Pri osebah, ki zdravila ne prenašajo ali imajo težave z ledvicami, se lahko uporabljajo manjši odmerki.
More patients remained non-smokers after treatment with Champix than after placebo: 40 weeks after the end of the treatment period, the percentage of patients who were still non-smokers was 23% among those who had taken Champix, and 9% among those who had taken a placebo. 
Po zaključku zdravljenja je več oseb ostalo nekadilcev v skupini, ki je jemala zdravilo Champix, kot v skupini, ki je prejemala placebo: 40 tednov po zaključku obdobja zdravljenja je bilo med osebami, ki so jemale zdravilo Champix, 23 % takih, ki še vedno niso kadile, med tistimi, ki so prejemale placebo, pa je takih bilo 9 % oseb.
For patients who have successfully stopped smoking after 12 weeks of treatment, doctors may choose to carry on treatment for another 12 weeks. 
Po koncu 12-tedenskega obdobja se lahko zdravniki pri osebah, ki so uspešno opustile kajenje, odločijo za nadaljevanje zdravljenja še nadaljnjih 12 tednov.
Another study compared Champix with placebo in patients who were allowed to choose their own target dates for quitting, which could be between one week and five weeks of starting treatment. 
V drugi študiji so zdravilo Champix primerjali s placebom pri kadilcih, ki so si lahko sami izbrali ciljni datum za opustitev kajenja, in sicer od enega do petih tednov po začetku zdravljenja.
The active substance in Champix, varenicline, can bind to some of these receptors, the α4β2 nicotinic acetylcholine receptors. 
Zdravilna učinkovina v zdravilu Champix je vareniklin, ki se veže na nekatere od teh receptorjev, in sicer na α4β2 nikotinske acetilholinske receptorje.
What is the risk associated with Champix? 
Kakšna tveganja so povezana z zdravilom Champix?
Nicotine acts in the nervous system, where it binds to receptors and triggers the release of a chemical messenger, dopamine, which plays a part in the pleasure derived from smoking. 
Nikotin deluje na živčevje, kjer se veže na receptorje in sproži sproščanje sporočilne molekule dopamin, ki je delno odgovorna za užitek pri kajenju.
In the study where patients were allowed to set their own target dates, Champix was also shown to be effective in helping patients to quit. 
Tudi v študiji, v kateri so si kadilci sami postavili datum prenehanja kajenja, se je zdravilo Champix izkazalo kot učinkovita pomoč pri opustitvi kajenja.
Why has Champix been approved? 
Zakaj je bilo zdravilo Champix odobreno?
Patients set themselves a target date for quitting and will usually start taking Champix one to two weeks before this date. 
Kadilci si morajo najprej postaviti datum, ko bodo prenehali kaditi, nato pa en teden ali dva pred tem datumom začnejo jemati zdravilo Champix.
What is Champix? 
Kaj je zdravilo Champix?
How has Champix been studied? 
Kako je bilo zdravilo Champix raziskano?
How does Champix work? 
Kako zdravilo Champix deluje?
What is Champix used for? 
Za kaj se zdravilo Champix uporablja?
How is Champix used? 
Kako se zdravilo Champix uporablja?
Both active substances have been available in the EU for a number of years: lamivudine has been authorised as Epivir since 1996 and zidovudine has been available in the EU since the mid-1980s. 
Obe zdravilni učinkovini sta v Evropski uniji (EU) na voljo že vrsto let: lamivudin kot zdravilo Epivir od leta 1996, zidovudin pa je v EU na voljo od sredine osemdesetih let prejšnjega stoletja.
Two medicines are bioequivalent when they produce the same levels of the active substance in the body. 
Dve zdravili sta biološko enakovredni takrat, kadar v telesu tvorita enako raven zdravilne učinkovine.
Patients who cannot swallow tablets may crush the tablets and add them to a small amount of food or drink immediately before swallowing it. 
Bolniki, ki ne morejo pogoltniti cele tablete, jo lahko zdrobijo in jo neposredno pred zaužitjem zmešajo z majhno količino hrane ali pijače.
In children (below 12 years of age) weighing between 14 and 30 kg, the number of tablets and half tablets to take depends on their weight. 
Pri otrocih (mlajših od 12 let), ki tehtajo med 14 in 30 kg, je število celih ali polovičnih tablet odvisno od njihove telesne mase.
The full EPAR for Lamivudine/Zidovudine Teva can be found on the Agency's website ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports. 
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo Lamivudine/Zidovudine Teva je na voljo na spletni strani agencije ema.europa.eu/Find medicine/Human medicines/European Public Assessment Reports.
The recommended dose of Lamivudine/Zidovudine Teva for patients over 12 years of age who weigh at least 30 kg is one tablet taken twice a day. 
Priporočeni odmerek zdravila Lamivudine/Zidovudine Teva pri bolnikih, starejših od 12 let, ki tehtajo najmanj 30 kg, je ena tableta dvakrat na dan.
For more information about treatment with Lamivudine/Zidovudine Teva, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist. 
Za več informacij o zdravljenju z zdravilom Lamivudine/Zidovudine Teva preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
Children weighing less than 14 kg will need to use separate oral solutions containing lamivudine and zidovudine. 
Pri otrocih, ki tehtajo manj kot 14 kg, bo treba uporabiti ločeni peroralni raztopini, ki vsebujeta lamivudin in zidovudin.
The European Commission granted a marketing authorisation valid throughout the European Union for Lamivudine/Zidovudine Teva on 28 February 2011. 
Evropska komisija je dovoljenje za promet z zdravilom Lamivudine Teva, veljavno po vsej Evropski uniji, izdala 28. februarja 2011.
Lamivudine/Zidovudine Teva is a medicine that contains two active substances, lamivudine (150 mg) and zidovudine (300 mg). 
Lamivudine/Zidovudine Teva je zdravilo, ki vsebuje dve zdravilni učinkovini, lamivudin (150 mg) in zidovudin (300 mg).
The tablets should ideally be swallowed without crushing. 
Tablete je najbolje pogoltniti cele, ne da bi jih prej zdrobili.
This means that Lamivudine/Zidovudine Teva is similar to a ‘reference medicine' already authorised in the European Union (EU) called Combivir. 
To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Combivir.
This is a summary of the European public assessment report (EPAR) for Lamivudine/Zidovudine Teva. 
To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Lamivudine/Zidovudine Teva.
If patients need to stop taking lamivudine or zidovudine, or need to take different doses because of problems with their kidneys, liver or blood, they will need to take medicines containing lamivudine or zidovudine separately. 
Če morajo bolniki zaradi težav z ledvicami, jetri ali krvjo prekiniti jemanje lamivudina ali zidovudina oziroma morajo spremeniti odmerke, morajo dobivati ločena zdravila, ki vsebujejo le lamivudin ali zidovudin.
Lamivudine/Zidovudine Teva does not cure HIV infection or AIDS, but it may delay the damage to the immune system and the development of infections and diseases associated with AIDS. 
Zdravilo Lamivudine/Zidovudine Tevane ne zdravi okužbe z virusom HIV ali aidsa, lahko pa upočasni slabšanje imunskega sistema ter razvoj okužb in bolezni, povezanih z aidsom.
Lamivudine/Zidovudine Teva, taken in combination with at least one other HIV medicine, reduces the amount of HIV in the blood and keeps it at a low level. 
Zdravilo Lamivudine/Zidovudine Teva v kombinaciji z vsaj enim zdravilom proti okužbi z virusom HIV zniža njegovo količino v krvi in jo zadržuje na nizki ravni.
Because Lamivudine/Zidovudine Teva is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's. 
Ker je zdravilo Lamivudine/Zidovudine Teva generično zdravilo, se šteje, da so njegove koristi in tveganja enaki kot pri referenčnem zdravilu.
Children taking Lamivudine/Zidovudine Teva should be closely monitored for side effects. 
Otroke, ki jemljejo zdravilo Lamivudine/Zidovudine Teva, je treba skrbno nadzorovati glede pojava neželenih učinkov.
It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Lamivudine/Zidovudine Teva. 
Pojasnjuje, kako je Odbor za zdravila za uporabo v humani medicini (CHMP) ocenil to zdravilo, na podlagi česar je oblikoval mnenje za izdajo dovoljenja za promet z njim in priporočila glede pogojev njegove uporabe.
Therefore, the CHMP's view was that, as for Combivir, the benefit outweighs the identified risk. 
Zato je menil, da njegove koristi enako kot pri zdravilu Combivir odtehtajo znana tveganja.
They both work in similar ways by blocking the activity of reverse transcriptase, an enzyme produced by HIV that allows it to infect cells and make more viruses. 
Učinkovini podobno zavirata delovanje reverzne transkriptaze, tj. encima, ki ga tvori virus HIV in ki omogoča okužbo celic ter nastajanje novih virusov.
The CHMP concluded that, in accordance with EU requirements, Lamivudine/Zidovudine Teva has been shown to have comparable quality and to be bioequivalent to Combivir. 
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da je bilo v skladu z zahtevami EU dokazano, da ima zdravilo Lamivudine/Zidovudine Teva primerljivo raven kakovosti kot zdravilo Combivir ter da mu je biološko enakovredno.
Both active substances in Lamivudine/Zidovudine Teva, lamivudine and zidovudine, are nucleoside reverse transcriptase inhibitors (NRTIs). 
Obe zdravilni učinkovini v zdravilu Lamivudine/Zidovudine Teva, lamivudin in zidovudin, sta zaviralca nukleozidne reverzne transkriptaze (NRTI).
Because Lamivudine/Zidovudine Teva is a generic medicine, studies in people have been limited to tests to determine that it is bioequivalent to the reference medicine, Combivir. 
Ker je zdravilo Lamivudine/Zidovudine Teva generično zdravilo, so bile študije omejene na preskuse za ugotavljanje, ali je biološko enakovredno referenčnemu zdravilu Combivir.